NCT02936232 Severe Sepsis and Septic Shock Registry
| NCT ID | NCT02936232 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2014-08 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2014-08 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to construct multi-center sepsis registry that can be used for data warehousing and clinical research.
Eligibility Criteria
Inclusion Criteria: * two of more systemic inflammatory reaction syndrome criteria fever \> 38.3 'C or hypothermia \< 36'C, tachycardia over 90 bpm tachypnea over 20 per minute, leukocytosis (WBC over 12k/microL) or leukopenia (WBC below 4k/microL) * suspected or proven infection * any organ dysfunction as follows: 1. cardiovascular (hypotension, systolic blood pressure \<90 mmHg, mean arterial pressure \<70mmHg) 2. tissue hypoperfusion (lactate above upper limits laboratory normal) 3. acute lung injury (PaO2/inspired oxygen fraction \< 250 in the absence of pneumonia, PaO2/inspired oxygen fraction \< 200 in the presence of pneumonia) 4. acute kidney injury (Urine output \< 0.5mL/kg/hr for at least 2 hrs Serum creatinine \> 2.0 mg/dL) 5. acute liver injury (Total bilirubin \> 2mg/dL) 6. acute coagulopathy (Platelet count \< 100,000/μL or prothrombin time, international normalized ratio \> 1.5) Exclusion Criteria: * age less than 18 years old * patients with cardiac arrest at presentation * patients with advanced directives not to deliver aggressive organ supportive management
Contact & Investigator
Gil Joon Suh, MD, PhD
STUDY DIRECTOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT02936232 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02936232 currently recruiting?
Yes, NCT02936232 is actively recruiting participants. Contact the research team at kanesu@gmail.com for enrollment information.
Where is the NCT02936232 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT02936232 clinical trial?
NCT02936232 is sponsored by Seoul National University Hospital. The principal investigator is Gil Joon Suh, MD, PhD at Seoul National University Hospital. The trial plans to enroll 3,000 participants.